Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 30 (cancelled)

31 (currently amended): A method for treating an ophthalmic disorder in a mammal, said method comprising administering to the eye of said mammal a lipid formulation, said lipid formulation comprising:

a lipid phase, said lipid phase comprising a phospholipid and a modifying agent, wherein said modifying agent is a ~~member selected from the group consisting of~~ cationic lipid[[s]] ~~and mucoadhesive compounds~~;

an aqueous phase; and

a therapeutic agent, wherein the therapeutic agent is diclofenac, or a pharmaceutically acceptable salt thereof;

wherein said therapeutic agent in said lipid formulation is useful for treating said ophthalmic disorder;

wherein said lipid formulation comprises about 0.001 to about 10.000 wt % of said lipid phase and about 90.000 wt % to about 99.999 wt % of said aqueous phase, and wherein said lipid phase comprises 0.1 to 90.0 wt% of the therapeutic agent, 0.01 to ~~10 wt%~~ 98.8 wt% phospholipid, 0.1 to 10 wt % modifying agent and 0.1 to 10 wt% antioxidant.

32 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is post-operative pain.

33 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is ocular inflammation.

34 (previously presented): The method in accordance with claim 33, wherein said ocular inflammation results from a member selected from the group consisting of iritis, conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion and blood-aqueous barrier disruption.

35 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is post-operative ocular inflammation.

36 (original): The method in accordance with claim 35, wherein said post-operative ocular inflammation results from a member selected from the group consisting of photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial keratotomy.

37 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is a fungal or bacterial infection.

38 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is herpes ophthalmicus.

39 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is endophthalmitis.

40 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is intraocular pressure.

41 - 42 (cancelled)

43 (currently amended): A method for treating or preventing ocular inflammation, paracentesis-induced miosis, cystoid macular edema and mydriasis, said method comprising administering a therapeutically effective amount of ~~one or more~~ a first non-steroidal

anti-inflammatory drug and optionally a second non-steroidal anti-inflammatory drugs encapsulated or contained within a liposome formulation, said liposome formulation comprising 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous phase, wherein said lipid phase comprises 0.1 to 90.0 wt% of said first anti-inflammatory drug, 0.01 to ~~10 wt%~~ 98.8 wt% phospholipid, 0.1 to 10 wt% modifying agents and 0.1 to 10 wt% antioxidant;

wherein said modifying agent is a cationic lipid;

wherein said first non-steroidal anti-inflammatory drug is diclofenac, or a pharmaceutically acceptable salt thereof.

44 (original): The method in accordance with claim 43, wherein said liposome formulation is applied topically, resulting in the transcorneal or transscleral passage or introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

45 - 46 (cancelled)

47 (currently amended): The method in accordance with claim 46, wherein said second non-steroidal anti-inflammatory drugs are selected from the group consisting of ketoprofen, flurbiprofen, ibuprofen, ~~diclofenac,~~ ketorolac, nepafenac, amfenac and suprofen.

48 (cancelled)

49 (previously presented): The method in accordance with claim 43, wherein said ocular inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis, post-operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion, blood-aqueous barrier disruption or ocular trauma.

50 (original): The method in accordance with claim 49, wherein said post-operative inflammation is caused by photorefractive keratectomy, cataract removal surgery, intraocular lens implantation or radial keratotomy.

51 - 52 (cancelled)